Modifications of the radiosensitivity of a renal cancer cell line as a consequence of stable TIMP-1 overexpression

References

• Araya J, Maruyama M, Sassa K, Fujita T, Hayashi R, Matsui S, Kashii T, Yamashita N, Sugiyama E, Kobayashi M. Ionizing radiation enhances matrix-metalloproteinase 2 production in human lung epithelial cells. American Journal of Physiology and Lung Cell Molecular Physiology 2001; 280: L30–L38
   PubMedGoogle Scholar
• Birkedal-Hansen H, Moore W GI, Bodden M K, Windsor L J, Birkedal-Hansen B, DeCarlo A, Engler J A. Matrix metalloproteinases: A review. Critical Reviews in Oral Biology and Medicine 1993; 4: 197–250
   PubMedGoogle Scholar
• Bloomston M, Shafii A, Zervos E E, Rosemurgy A S. TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. Journal of Surgery Research 2002; 102: 39–44
   PubMed Web of Science ®Google Scholar
• Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: An overview. Molecular Cell Biochemistry 2003; 253: 269–285
   PubMed Web of Science ®Google Scholar
• Cockett M I, Murphy G, Birch M L, O'Connell L, Crabbe T, Milican A T, Hart I R, Docherty A SP. Matrix metalloproteinases and metastatic cancer. Biochemical Society Symposium 1998; 63: 295–313
   PubMedGoogle Scholar
• Cordes N, Blaese M A, Plasswilm L, Rodemann H P, van Beuningen D. Fibronectin and laminin increase resistance to ionising radiation and the cytotoxic drug Ukrain® in human tumour and normal cells in vitro. International Journal of Radiation Biology 2003; 79: 709–720
   PubMed Web of Science ®Google Scholar
• Cordes N, Hansmeier B, Beinke C, Meineke V, van Beuningen D. Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines. British Journal of Cancer 2003; 89: 2122–2132
   PubMed Web of Science ®Google Scholar
• Daza P, Schubler H, McMillan T J, Girod S C, Pfeiffer P. Radiosensitivity and double-strand break rejoining in tumorigenic and non-tumorigenic human epithelial cell lines. International Journal of Radiation Biology 1997; 72: 91–100
   PubMedGoogle Scholar
• Das U. A radical approach to cancer. Medical Science Monitor 2002; 8: RA79–RA92
   PubMedGoogle Scholar
• Hahn-Dantona E, Ramos-DeSimone N, Sipley J, Nagase H, French D L, Quigley J P. Activation of proMMP-9 by a plasmin MMP-3 cascade in a tumour cell model. Annals of the New York Academy of Sciences 1999; 878: 372–387
   PubMed Web of Science ®Google Scholar
• Heinzer H, Huland E, Huland H. Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer. World Journal of Urology 2001; 19: 111–119
   PubMedGoogle Scholar
• Kallakury B V, Karikehalli S, Haholu A, Sheehan C E, Azumi N, Ross J S. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clinical Cancer Research 2001; 7: 3113–3119
   PubMed Web of Science ®Google Scholar
• Knox S J, Goris M L, Wessels B W. Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiotherapy and Oncology 1992; 23: 111–117
   PubMed Web of Science ®Google Scholar
• Kugler A, Hammerlein B, Thelen P, Kallerhoff M, Radzun H J, Ringert H R. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. Journal of Urology 1998; 160: 1914–1918
   PubMedGoogle Scholar
• Leeman M F, Curran S, Murray G I. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. Journal of Pathology 2003; 201: 528–534
   PubMed Web of Science ®Google Scholar
• Liotta L A, Steeg P S, Stetler-Stevenson W G. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991; 64: 327–336
   PubMed Web of Science ®Google Scholar
• Makarewicz R, Zarzycka M, Kulinska G, Windorbska W. The value of postoperative radiotherapy in advanced renal cell cancer. Neoplasma 1998; 45: 380–383
   PubMed Web of Science ®Google Scholar
• Maskos K, Bode W. Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases. Molecular Biotechnology 2003; 25: 241–266
   PubMed Web of Science ®Google Scholar
• McElligott A M, Baker A H, McGlynn H. Matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase regulation of the invasion potential of a metastatic renal cancer cell line. Biochemical Society Transanctions 1997; 25: 147S
   Google Scholar
• McKelvey-Martin V J, Green M HL, Schmezer P, Pool-Zobel B L, DeMeo M P, Collins A. The single cell gel electrophoresis assay (comet assay): A European review. Mutation Research 1993; 288: 47–63
   PubMed Web of Science ®Google Scholar
• Mejean A, Oudard S, Thiounn N. Prognostic factors of renal cell carcinoma. Journal of Urology 2003; 169: 821–827
   PubMed Web of Science ®Google Scholar
• Nakopoulou L, Tsirmpa I, Alexandrou P, Louvrou A, Ampela C, Markaki S, Davaris P S. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Research and Treatment 2003; 77: 145–155
   PubMed Web of Science ®Google Scholar
• Nelson A R, Fingleton B, Rothenberg M L, Matrisian L. Matrix metalloproteinases: Biological activity and clinical implications. Journal of Clinical Oncology 2000; 18: 1135–1147
   PubMed Web of Science ®Google Scholar
• Nguyen M, Arkell J, Jackson C J. Human endothelial gelatinases and angiogenesis. International Journal of Biochemistry and Cell Biology 2001; 33: 960–970
   PubMed Web of Science ®Google Scholar
• Nirmala S, Jasti S L, Sawaya R, Kyritsis A P, Konduri S D, Ali-Osman F, Rao J S, Mohanam S. Effects of radiation on the levels of MMP-2, MMP-9 and TIMP-1 during morphogenic glial-endothelial cell interactions. International Journal of Cancer 2000; 88: 766–771
   PubMedGoogle Scholar
• Nunez M I, McMillan T J, Valenzuela M T, Ruiz de Almodovar J M, Pedraza V. Relationship between DNA damage, rejoining and cell killing by radiation in mammalian cells. Radiotherapy and Oncology 1996; 39: 155–165
   PubMed Web of Science ®Google Scholar
• Olive P L, Banath J P, Durand R E. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the “comet” assay. Radiation Research 1990; 122: 86–94
   PubMed Web of Science ®Google Scholar
• Parsons S L, Watson S A, Brown P D, Collins H M, Steele R JC. Matrix metalloproteinases. British Journal of Surgery 1997; 84: 160–166
   PubMed Web of Science ®Google Scholar
• Pawlik T M, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. International Journal of Radiation, Oncology, Biology, Physics 2004; 59: 928–942
   PubMed Web of Science ®Google Scholar
• Ramnath N, Creaven P J. Matrix metalloproteinase inhibitors. Current Oncology Reports 2004; 6: 96–102
   PubMedGoogle Scholar
• Reid H M, McElligott A M, McGlynn H. Phenotypic alterations in Caki-1 cells as a consequence of TIMP-1 overexpression. Cancer Letters 2001; 169: 189–198
   PubMedGoogle Scholar
• Slaton J W, Inoue K, Perrotte P, El-Naggar A K, Swanson D A, Fidler I J, Dinney C P. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. American Journal of Pathology 2001; 158: 735–743
   PubMed Web of Science ®Google Scholar
• Smyth A, McGlynn H. Modifications of the radiosensitivity of a renal cancer cell line as a consequence of polyunsaturated fatty acid supplementation. Nutrition Research 2005; 25: 65–77
   Google Scholar
• Sun Y, Wicha M, Leopold W R. Regulation of metastasis-related gene expression by p53: A potential clinical implication. Molecular Carcinogenesis 1999; 24: 25–28
   PubMedGoogle Scholar
• Susskind H, Hymowitz M H, Lau Y J, Atkins H L, Hurewitz A N, Valentine E S, Meek A G, Zucker S. Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy. International Journal of Radiation Oncology, Biology, Physics 2003; 56: 1161–1169
   PubMed Web of Science ®Google Scholar
• Takahashi M, Oka N, Naroda T, Nishitani M A, Kanda K, Kanayama H O, Kagawa S. Prognostic significance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma. International Journal of Urology 2002; 9: 531–538
   PubMedGoogle Scholar
• Tsuruda T, Costello-Boerrigter L C, Burnett J C, Jr. Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Fail Reviews 2004; 9: 53–61
   PubMed Web of Science ®Google Scholar
• Wang J L, Sun Y, Wu S. Gamma-irradiation induces matrix metalloproteinase II expression in a p53-dependent manner. Molecular Carcinogenesis 2000; 27: 252–258
   PubMed Web of Science ®Google Scholar